Decoy Therapeutics Inc. (NASDAQ:DCOY)
| Market Cap | 824.55K-96.9% |
| Revenue (ttm) | 0 |
| Net Income | -14.45M-183.1% |
| EPS | -29.09+40.4% |
| Shares Out | 531.97K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,135 |
| Open | 1.58 |
| Previous Close | 1.61 |
| Day's Range | 1.52 - 1.62 |
| 52-Week Range | 1.51 - 55.92 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
Insiders here have filed 10 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About DCOY
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DCOY stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DCOY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DCOY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DCOY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DCOY Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Loss from operations | $2.63M | 64.78% |
| Professional services and Consulting | $684.04K | 16.84% |
| Personnel cost | $428.92K | 10.56% |
| Grant Revenue | $227.63K | 5.60% |
| Facility cost and other | $90.14K | 2.22% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DCOY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DCOY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DCOY
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $12.30K |
| MEDXHorizon Kinetics Medical ETF | $32 |
Estimated from each fund’s disclosed top holdings × AUM
DCOY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DCOY’s recent data — informational, not investment advice